What's new? Log in Free sign up

Industry / Pharmaceutical Preparation Manufacturing

Trending Companies

Companies in the news

$100 Invested In This Stock 10 Years Ago Would Be Worth $500 Today

Pfizer Announced Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial; Said Study Demonstrated Statistically Significant Reduction In Annualized Bleeding Rate Vs Prophylaxis, On-demand Intravenous Regimens

Horizon Therapeutics

10 Health Care Stocks With Whale Alerts In Today's Session

Madrigal Pharmaceuticals

10 Health Care Stocks Whale Activity In Today's Session

Viking Therapeutics

10 Health Care Stocks Whale Activity In Today's Session

Lilly(Eli) & Co

Cantor Fitzgerald Reiterates Overweight on Eli Lilly, Maintains $485 Price Target

Johnson & Johnson

Citigroup Reinstates Buy on Johnson & Johnson, Announces $185 Price Target

10 Health Care Stocks With Whale Alerts In Today's Session

New England Journal Of Medicine Publishes Results From Phase 3 Induction And Maintenance Programs Evaluating Upadacitinib In Crohn's Disease

Argus Research Maintains Buy on AstraZeneca, Lowers Price Target to $80

Latest filings

All filings

CANF Can-Fite Biopharma

Report of Foreign Private Issuer

Trevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term Milestones

TAK Takeda Pharmaceutical

Current report (foreign)

TAK Takeda Pharmaceutical

Current report (foreign)

TAK Takeda Pharmaceutical

Current report (foreign)

TAK Takeda Pharmaceutical

Current report (foreign)

ASND Ascendis Pharma A/S

Conflict minerals disclosure

COCP Cocrystal Pharma

Notice of effectiveness

VIRX Viracta Therapeutics

Notice of proposed sale of securities

Notice of proposed sale of securities

Upcoming Earnings Releases

Earnings calendar

NeuroSense Therapeutics

Pasithea Therapeutics

Scopus BioPharma

Alterity Therapeutics

Can-Fite Biopharma

Ayala Pharmaceuticals

Imago BioSciences

Biohaven Pharmaceutical Holding

Latest IPO Filings (S1/F1/S11)

IPO calendar

AGRX Agile Therapeutics

NEPT Neptune Wellness Solutions

ABVC ABVC BioPharma

ENSC Ensysce Biosciences

PHIO Phio Pharmaceuticals

AYTU Aytu BioPharma

ADXN Addex Therapeutics

KPRX Kiora Pharmaceuticals

ATNF 180 Life Sciences

Stock splits Upcoming and recent stock splits

Splits calendar

Propanc Biopharma

Evofem Biosciences

Tonix Pharmaceuticals Holding

Hepion Pharmaceuticals

Xenetic Biosciences

Galmed Pharmaceuticals

Adamis Pharmaceuticals

Sigilon Therapeutics

News

From Benzinga Pro

Bristol Myers Squibb Says FDA Accepts For Priority Review Its Application For Repotrectinib For Treatment Of Patients With Locally Advanced Or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

Pfizer Announced Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial; Said Study Demonstrated Statistically Significant Reduction In Annualized Bleeding Rate Vs Prophylaxis, On-demand Intravenous Regimens

Needham Reiterates Buy on Collegium Pharmaceutical, Maintains $35 Price Target

Needham Reiterates Buy on Harmony Biosciences, Maintains $67 Price Target

Needham Reiterates Buy on Jazz Pharmaceuticals, Raises Price Target to $226

Gaotu Techedu, Iovance Biotherapeutics And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session

HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $35 Price Target

Immuron Begins Recruitment Of Travelan Clinical Study

HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $66 Price Target

William Blair Initiates Coverage On Vertex Pharmaceuticals with Outperform Rating

Press releases

From Benzinga Pro

Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Atea Pharmaceuticals' Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners' Affiliate, Concentra Biosciences

BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia

Tonix Pharmaceuticals Announces Presentation at the 2023 BIO International Convention

Presenting on the Emerging Growth Conference on May 31 Register Now

Can-Fite: Namodenoson's Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)

Health Canada Approves(PR) BRUKINSA® (zanubrutinib) for the Treatment of Chronic Lymphocytic Leukemia (CLL), the Most Common Leukemia in Adults

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial

Immunic to Participate in Scientific and Investor Conferences in June

Community annotations

(No comment added)

(No comment added)

(No comment added)

(No comment added)

(No comment added)

(No comment added)

(No comment added)

(No comment added)

(No comment added)

Community notes

Transcripts

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Patents

Method for automatic sea lice monitoring in salmon aquaculture

Balloon catheter with diagnostic electrodes, far field electrodes, and guidewire

Foldable 2-D CMUT-on-CMOS arrays

Dilation system

Surgical instrument comprising a sensing system

Surgical instruments with segmented flexible drive arrangements

Method of applying buttress to end effector of surgical stapler

Methods and systems for attaching tissue to bone

Articulation joint having an inner guide

Motor-driven surgical cutting and fastening instrument with tactile position feedback

Reddit threads

What are your biggest positions today? In 10 years what do you hope they will be?

Scans for swing trades

How will these new weight-loss drugs impact various markets?

Pepsi charts 5 year, 10 year, and all since 1984

Burned By The Motley Fool Stock Advisor?

April: +$40,146. Finally achieved a perfect month. Here is why I pursue a more "stable" equity curve, and what changes I made to my strategy to achieve this consistency.

Next Week Earnings Releases by Implied Movement

smallstreetbets

Daily Discussion Thread - April 28th, 2023

If you had $100,000 to invest would you go all in on dividends? If so how would you split it up?

$EPAZ OTC Stocks Poised To Pop On News (EPAZ, GTCH, SMCE, AITX)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.